MedCity News
NOVEMBER 5, 2023
Available atopic dermatitis drugs work by blocking inflammation, but Triveni Bio is developing an antibody that addresses a root cause of the chronic condition. The startup is out of stealth to advance its lead program and a pipeline of other inflammation and immunology drugs.
pharmaphorum
NOVEMBER 5, 2023
Innoviva’s ‘game changer’ antibiotic tackles gonorrhoea Phil.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
NOVEMBER 5, 2023
Despite most insurer execs saying that digital transformation is a top priority, only 8% believe the majority of their staff embrace digital transformation, according to data from West Monroe.
Cesare Ferrari
NOVEMBER 5, 2023
In my previous post, I discussed key accounts and their role in product development. Today I would take the analysis several steps further by sharing a few common mistakes in selecting and categorizing key accounts. In my experience in medical device marketing, suppliers and distributors are frequently small and medium size companies and I have always believed their process to properly identify and select their key accounts can be improved.
MedCity News
NOVEMBER 5, 2023
Medicare needs to incentivize providers by reimbursing them for identifying and addressing social determinants of health. Doing so will ultimately improve patient health outcomes and simultaneously save risk-bearing organizations money.
Contrarian Sales Techniques
NOVEMBER 5, 2023
In the ever-evolving landscape of global commerce, the art of selling has become a nuanced ballet of persuasion, analytics, and strategy. The difference between stagnant sales and exponential growth can often be traced back to a company’s willingness to adapt and innovate in its sales strategy. As we pull back the curtain on the sales strategies of industry titans, we find actionable insights ripe for the picking.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaTech
NOVEMBER 5, 2023
When a large CDMO couldn’t give a mid-size pharma company the proper attention, Adare stepped in to help manufacture CTM batches and get their project to the clinic quickly.
MedCity News
NOVEMBER 5, 2023
The “right” investment banker for you with the appropriate experience can not only tell you what your company is worth, they can also utilize their expertise to establish and run an appropriate, bespoke transaction process that will serve to reduce risk and maximally benefit you and your company’s future potential, valuation or even sale price – and they should be equally willing and able to
Pharmacy Times
NOVEMBER 5, 2023
Other than dialysis, Shah notes that patients with kidney disease who are pregnant can receive either nifedipine or labetalol to control blood pressure.
Pharmaceutical Technology
NOVEMBER 5, 2023
Two more medtech darlings have closed their doors this week, signalling an end to the funding rush of Covid.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmacy Times
NOVEMBER 5, 2023
Nickolas also describes how the use of novel imaging technologies, microRNA, and transcriptomics help experts better understand underlying pathogenesis of ROD.
Pharmaceutical Technology
NOVEMBER 5, 2023
ABP-671 is under clinical development by Jiangsu Atom Bioscience and Pharmaceutical and currently in Phase II for Hyperuricemia.
Pharmacy Times
NOVEMBER 5, 2023
Deep-rooted discrimination and stigma can contribute to stressors that worsen disease progression and access to care, according to experts.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myeloproliferative Disorders.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PharmaTech
NOVEMBER 5, 2023
In this article, gain insights into how early-stage pharmaceutical product development is foundational for successful clinical trials and regulatory approvals, and why collaboration with experienced partners like CDMOs is essential.
Pharmaceutical Technology
NOVEMBER 5, 2023
XB-002 is under clinical development by Exelixis and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
PharmaTech
NOVEMBER 5, 2023
A discussion of the FDA's guidance on nitrosamine impurities, various approaches for reducing the presence of impurities, and how Adare's unique nitrosamine mitigation process can help products achieve compliance.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PharmaTech
NOVEMBER 5, 2023
To help improve adherence in children, drug developers need to consider innovative new dosage forms that can deliver flexible and convenient medications for young patients.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).
Pharmaceutical Technology
NOVEMBER 5, 2023
BGB-16673 is under clinical development by BeiGene and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-100 is under clinical development by Alto Neuroscience and currently in Phase II for Post-Traumatic Stress Disorder (PTSD).
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-100 is under clinical development by Alto Neuroscience and currently in Phase II for Post-Traumatic Stress Disorder (PTSD).
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.
Pharmaceutical Technology
NOVEMBER 5, 2023
Birociclib is under clinical development by Sihuan Pharmaceutical Holdings Group and currently in Phase I for Solid Tumor.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myeloproliferative Disorders.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-300 is under clinical development by Alto Neuroscience and currently in Phase II for Major Depressive Disorder.
Pharmaceutical Technology
NOVEMBER 5, 2023
ABSK-021 is under clinical development by Abbisko Therapeutics and currently in Phase I for Small-Cell Lung Cancer.
Pharmaceutical Technology
NOVEMBER 5, 2023
(Favezelimab + pembrolizumab) is under clinical development by Merck and currently in Phase II for Bladder Cancer.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myelodysplastic Syndrome.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
122 
Let's personalize your content